From June 3-6, 2024, the 2024 Biotechnology Innovation Organization International Convention (“BIO 2024”) will be held in San Diego Convention Center, California, USA. Henlius, along with its wholly-owned subsidiary, Aton Biotech, a biologics CDMO will showcase a wide range of innovative research and development accomplishments for conference attendees. As an innovative global biopharma company, Henlius has always been guided by clinical needs to build up a high-quality, affordable and differentiated pipeline to effectively meet the needs of patients and the market. Currently, its product pipeline covers more than 50 molecules with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

The BIO International Convention is the largest gathering of the biotechnology industry worldwide, bringing together leading biopharmaceutical companies, investors, and partners from around the globe. Numerous partnering meetings are organized during the conference. This year marks the sixth consecutive year of Henlius's participation in this prestigious event.

During BIO 2024, the company will be at Booth #1719 with 5 launched products, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name: HERCESSI™ in the U.S and Zercepac^® in Europe) and its innovative product HANSIZHUANG, the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer. On April 26, 2024, Henlius’ self-developed and -manufactured trastuzumab biosimilar HERCESSI™ (trade name: HANQUYOU in China and Zercepac^® in Europe) receives FDA approval in the United States. HANQUYOU is a China-developed mAb biosimilar approved in China, Europe, and U.S. It has been approved in over 40 countries and regions, including the United Kingdom, France, Germany, Switzerland, Australia, Finland, Spain, Argentina, Saudi Arabia, and Thailand, covering Asia, Europe, Latin America, North America, and Oceania. To date, HLX02 has benefited over 190,000 patients.

Up to now, the company has collaborated with international partners such as Accord, Abbott, Eurofarma, Elea and KGbio to globalize its 8 products including HANLIKANG, HANQUYOU and HANSIZHUANG, covering mainstream biopharmaceutical markets in Europe, the United States, and numerous emerging markets, further expanding its global presence. Furthermore, the company actively explores new targets and mechanisms, continuously expanding its product portfolio in terms of therapeutic areas and novel molecule types. Recently, Henlius' investigational new drug (IND) application for phase 3 international multicenter clinical study of Henlius’ novel anti-HER2 mAb, HLX22, has been approved by the FDA. Besides, the company is promoting the clinical development of two potential first/best-in-class products, HLX42 (EGFR ADC) and HLX43 (PD-L1 ADC). In addition，Henlius is dedicated to facilitate high-concentration drug subcutaneous administration, the company has established a hyaluronidase-based subcutaneous injection drug product (DP) development platform.

Henlius is determined to offer high-quality, affordable, and innovative biologic medicines for patients worldwide, focuses on game-changing innovations, and aggressively pursues anti-tumour research and international collaboration. We warmly invite you to visit and connect with us at booth #1719 at San Diego Convention Center.